These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 22803644

  • 1. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB, Hamlin PJ.
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract] [Full Text] [Related]

  • 2. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A, Gisbert JP.
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract] [Full Text] [Related]

  • 3. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A, Elisei W, Picchio M, Penna A.
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract] [Full Text] [Related]

  • 4. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A, Bonnet D, Thebault S, Alric L.
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract] [Full Text] [Related]

  • 5. [Adalimumab in Crohn's disease - data from real life].
    López San Román A, Van Domselaar M, Garrido E.
    Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
    [No Abstract] [Full Text] [Related]

  • 6. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L.
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC.
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [Abstract] [Full Text] [Related]

  • 11. Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
    Magro F, Coelho R, Guimarães LS, Silva M, Peixoto A, Lopes S, Macedo G.
    Scand J Gastroenterol; 2016 Aug; 51(4):511-2. PubMed ID: 26523855
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
    Kabaçam G, Törüner M.
    Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB, Sagynbaeva VÉ.
    Eksp Klin Gastroenterol; 2013 Mar; (7):18-22. PubMed ID: 24772870
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.